Nemluvio (nemolizumab-ilto) — Medica

Atopic dermatitis

Initial criteria

age ≥ 12 years
atopic dermatitis involvement estimated to be ≥ 10% of the body surface area
patient has tried at least one medium-, medium-high, high-, and/or super-high-potency prescription topical corticosteroid applied daily for at least 28 consecutive days with inadequate efficacy according to the prescriber
for initial therapy, the medication will be used in combination with a topical corticosteroid and/or a topical calcineurin inhibitor OR the patient’s atopic dermatitis has sufficiently improved with Nemluvio and topical therapy has been discontinued
prescribed by or in consultation with an allergist, immunologist, or dermatologist

patient has already received at least 4 months of therapy with Nemluvio
patient has responded to therapy as determined by the prescriber (e.g., marked improvements in erythema, induration/papulation/edema, excoriations, and lichenification; reduced pruritus; decreased requirement for other topical or systemic therapies; reduced body surface area affected)

initial 4 months; reauthorization 1 year